Search Result

Results for "

insulin receptor kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	IGF-1R (12) Insulin Receptor (21) Adenosine Kinase (2) Akt (3) Anaplastic lymphoma kinase (ALK) (9) Apoptosis (9) Autophagy (1) EGFR (3) Endogenous Metabolite (2) Endothelin Receptor (1) ERK (4) FGFR (2) Free Fatty Acid Receptor (2) G Protein-coupled Receptor Kinase (GRK) (2) GLP Receptor (1) Isotope-Labeled Compounds (1) Itk (1) JAK (1) MAP3K (1) MAPKAPK2 (MK2) (1) Mitochondrial Metabolism (1) mRNA (1) Myosin (1) NO Synthase (1) PDGFR (3) Phosphatase (1) Potassium Channel (2) PTEN (1) Reference Standards (5) ROCK (1) Tie (2) Tyrosinase (1) VEGFR (2)
By Research Areas:	Cancer (23) Cardiovascular Disease (4) Endocrinology (6) Inflammation/Immunology (6) Metabolic Disease (20) Neurological Disease (5)
Oligonucleotides:	mRNA (1) Interleukin & Receptors (1)

Inhibitors & Agonists

Bibliotecas de Screening

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Insulin Receptor IGF-1R IDE

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-15424

5-Iodotubercidin Maximum Cited Publications 11 Publications Verification NSC 113939; 5-ITu	Adenosine Kinase	Cancer
5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC₅₀ of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin .

HY-15589

GW9508 5+ Cited Publications	Free Fatty Acid Receptor Potassium Channel	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GW9508 is a potent and selective *G protein-coupled receptors* FFA1 (GPR40) and GPR120 agonist with pEC₅₀s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120*. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin* secretagogue and an ATP-sensitive potassium (K_ATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .

HY-10262

BMS-536924 5+ Cited Publications	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
BMS-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC₅₀s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity .

HY-10524

GSK1904529A 5+ Cited Publications	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC₅₀s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC₅₀>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity .

HY-P1856

Proinsulin C-peptide (human) 1 Publications Verification	Insulin Receptor PDGFR MAPKAPK2 (MK2)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Proinsulin C-peptide (human) is a peptide consisting of 31 amino acids that links the A and B chains of proinsulin to ensure its correct folding. Proinsulin C-peptide (human) inhibits the high glucose-induced increase in PDGF-β receptor protein expression and the phosphorylation of p42/p44 MAP kinase. Proinsulin C-peptide (human) increases the deformability of erythrocytes derived from type 1 diabetes, inhibits insulin-induced neointimal thickening, and suppresses the proliferation of rat aortic smooth muscle cells cultured under high-glucose conditions .

HY-13896

PD168393 3 Publications Verification	EGFR Autophagy Apoptosis	Cancer
PD168393 is a potent, selective and cell-permeable inhibitor of EGFR tyrosine kinase and ErbB2. PD168393 irreversiblely inactivates EGF receptor ( IC₅₀=0.7 nM) and is inactive against insulin receptor, PDGFR, FGFR and PKC .

HY-10252

NVP-ADW742 3 Publications Verification ADW742; GSK 552602A; ADW	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC₅₀ of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC₅₀ of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells .

HY-114367

Delphinidin 3-rutinoside chloride 1 Publications Verification Delphinidin 3-O-rutinoside chloride	Endothelin Receptor NO Synthase Myosin GLP Receptor	Neurological Disease Metabolic Disease
Delphinidin 3-rutinoside chloride is an anthocyanin component. Delphinidin 3-rutinoside chloride is isolable from the fruits of blackcurrant Ribes nigrum L. Delphinidin 3-rutinoside chloride activates the ET_B receptor and stimulates the NO/cGMP pathway. Delphinidin 3-rutinoside chloride increases cyclic guanosine monophosphate production and reduces the phosphorylation level of Myosin regulatory light chain. Delphinidin 3-rutinoside chloride stimulates GLP-1 secretion. It significantly induces relaxation of bovine ciliary muscle strips contracted by ET-1 and inhibits ET-1-induced contraction of bovine ciliary muscle strips. Delphinidin 3-rutinoside chloride is applicable to research related to type 2 diabetes .

HY-119152

CMX-2043	Insulin Receptor Tyrosinase Akt	Others
CMX-2043 is a novel analogue of α-Lipoic Acid (HY-N0492). CMX-2043 is effective in antioxidant effect, activation of **insulin receptor kinase*, soluble tyrosine kinase, and Akt* phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model .

HY-112411

PD 174265	EGFR ERK PDGFR FGFR	Neurological Disease Inflammation/Immunology
PD 174265 is a highly selective, reversible EGFR/ErbB2 tyrosine kinase inhibitor (IC₅₀=0.45 nM) and cell differentiation inducer. By blocking receptor autophosphorylation and the downstream ERK signaling pathway (with an IC₅₀ of 0.45 μM for full-length ERK), PD 174265 effectively inhibits tumor growth and exhibits antitumor activity without obvious toxicity in in vivo models. PD 174265 drives oligodendrocyte precursor cells to switch from a proliferative state to a differentiated state, significantly upregulates the expression of myelin proteins such as CNP, PLP and MBP, and induces neurite branching. PD 174265 shows no inhibitory effect on other kinases including insulin, PDGF and basic FGF receptors, and serves as a crucial tool molecule for investigating the treatment of human epidermoid carcinoma and the mechanism of myelin repair in multiple sclerosis .

HY-18764

BpV(pic) potassium hydrate 1 Publications Verification	PTEN	Metabolic Disease
BpV(pic) potassium hydrate is a PTEN inhibitor with IC₅₀ 31 nM. BpV(pic) potassium hydrate is also an insulin simulator that activates insulin receptor kinase in cultured liver cancer cells, stimulates adipogenesis in adipocytes, and inhibits the dephosphorylation of autophosphorylated insulin receptors and epidermal growth factor receptors in rat hepatosomes .

HY-153830

LacCer (d18:1/16:0) C16 Lactosylceramide (d18:1/16:0)	Endogenous Metabolite	Neurological Disease Metabolic Disease
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

HY-136561

GRK5-IN-2 4 Publications Verification	G Protein-coupled Receptor Kinase (GRK) ERK	Metabolic Disease
GRK5-IN-2 (compound 707), a pyridine-based bicyclic compound, is a potent *G-protein-coupled receptor* kinase 5 (GRK5) inhibitor with an IC₅₀** of 49.7 μM. GRK5-IN-2 regulates the expression and/or release of insulin and is useful for the metabolic disease research .

HY-124097

HNMPA-(AM)3	Insulin Receptor	Metabolic Disease
HNMPA-(AM)3 is a cell-permeable and selective **insulin receptor tyrosine kinase inhibitor analog of HNMPA. HNMPA-(AM)3 greatly inhibits the ability of prothoracicotropic hormone (PTTH) to activate ERK phosphorylation and stimulate ecdysteroidogenesis. HNMPA-(AM)3 is also effective in inhibiting ecdysteroid production (IC₅₀*=14.2 μM) and insulin* receptor activity (IC₅₀ is 14.2 μM and 200 μM in mosquitoes and mammals, respectively) .

HY-135680

I-OMe-Tyrphostin AG 538 1 Publications Verification I-OMe-AG 538	IGF-1R	Metabolic Disease Cancer
I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells.?I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of *phosphatidylinositol-5-phosphate 4-kinase* α (PI5P4Kα), with an IC₅₀**?of 1 μM .

HY-P5431

Insulin receptor (1142-1153), pTyr1150	Insulin Receptor	Others
Insulin receptor (1142-1153), pTyr1150 is a biological active peptide. (Peptide used as insulin receptor tyrosine kinase substrate.)

HY-118203

SU4984	FGFR PDGFR Insulin Receptor	Cancer
SU4984 is a protein tyrosine kinase inhibitor, with an IC₅₀ of 10-20 μM for *fibroblast growth factor receptor* 1 (FGFR1)*. SU4984 is also inhibits platelet-derived growth factor receptor, and *insulin receptor**. SU4984 can be used for the research of cancer .

HY-15424R

5-Iodotubercidin (Standard) NSC 113939 (Standard); 5-ITu (Standard)	Adenosine Kinase Reference Standards	Cancer
5-Iodotubercidin (Standard) is the analytical standard of 5-Iodotubercidin. This product is intended for research and analytical applications. 5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC50 of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin .

HY-15589R

GW9508 (Standard)	Free Fatty Acid Receptor Potassium Channel Reference Standards	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GW9508 (Standard) is the analytical standard of GW9508. This product is intended for research and analytical applications. GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities .

HY-101962

HNMPA	Insulin Receptor	Metabolic Disease
HNMPA is a membrane impermeable **insulin receptor tyrosine kinase** inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities

HY-P1790

Axltide	JAK	Metabolic Disease
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .

HY-13232

ITK antagonist	Itk	Inflammation/Immunology
ITK antagonist (compound 10 n) is a potent, orally active and selective ITK (Interleukin-2 inducible T-cell kinase) antagonist (IC₅₀=1 and 20 nM in different assays). ITK antagonist inhibits insulin receptor kinase (IRK) with an IC₅₀ of 160 nM .

HY-E70730

INSR Recombinant Human Active Protein Kinase	IGF-1R	Metabolic Disease
The whole IGF axis constitutes an interactive network composed of the peptide-ligands IGF1, IGF2 and insulin, and the receptors IGF1R, IGF2R and insulin receptor (INSR) as IGF binding proteins (IGFBPs). The INSR itself appears in two isoforms, INSRA and INSRB differing in 12 amino acids encoded by exon 11. INSR Recombinant Human Active Protein Kinase is a recombinant INSR protein that can be used to study INSR-related functions .

HY-162506

IGF-1R inhibitor-3	IGF-1R	Cancer
IGF-1R inhibitor-3 (Compound C11) is an allosteric inhibitor for insulin-like growth factor receptor 1 kinase (IGF-1R), with an IC₅₀ of 0.2 μM .

HY-E70832

IRR Recombinant Human Active Protein Kinase	Insulin Receptor	Metabolic Disease
IRR is a member of the insulin receptor (IR) family. IRR activation by alkali is determined by its N-terminal extracellular region. IRR Recombinant Human Active Protein Kinase is a recombinant IRR protein that can be used to study IRR-related functions .

HY-118046

GSK2163632A	ROCK IGF-1R G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
GSK2163632A is a selective *G protein-coupled receptor* kinase (GRK) inhibitor that can be used as a probe for studying heart failure and Parkinson's disease. GSK2163632A potently inhibits GRK1 and GRK5*, and also inhibits Rho-associated coiled-coil kinase* (ROCK) and insulin-like growth factor receptor IGF-1R. GSK2163632A binds to GRK2 in a manner similar to Paroxetine (HY-122272).

HY-10252A

cis-NVP-ADW742 cis-ADW742; cis-GSK 552602A; cis-ADW	IGF-1R Insulin Receptor Apoptosis	Inflammation/Immunology
cis-NVP-ADW742 (cis-ADW742) is a cis isomer of NVP-ADW742 (HY-10252). NVP-ADW742 is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC₅₀ of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC₅₀ of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells .

HY-153830S

LacCer (d18:1/16:0)-d3 C16 Lactosylceramide (d18:1/16:0)-d₃	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease Metabolic Disease
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0))-d₃ is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. LacCer (d18:1/16:0) is also upregulated in a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder). LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

HY-P1776

[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)	Insulin Receptor	Metabolic Disease
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates .

HY-138842

DDN	Insulin Receptor Akt ERK	Metabolic Disease
DDN is a selective insulin receptor (Insulin *Receptor) activator, an insulin* sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .

HY-E70647

ALK R1275Q Recombinant Human Active Protein Kinase	Anaplastic lymphoma kinase (ALK)	Cancer
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK has multiple mutants. ALK R1275Q is commonly found in neuroblastoma (NB). ALK R1275Q Recombinant Human Active Protein Kinase is a recombinant ALK R1275Q protein that can be used to study ALK R1275Q-related functions .

HY-E70643

ALK F1174L Recombinant Human Active Protein Kinase	Anaplastic lymphoma kinase (ALK)	Cancer
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK has multiple mutants. ALK-F1174L is commonly found in neuroblastoma (NB). ALK-F1174L Recombinant Human Active Protein Kinase is a recombinant ALK-F1174L protein that can be used to study ALK-F1174L-related functions .

HY-E70644

ALK F1174S Recombinant Human Active Protein Kinase	Anaplastic lymphoma kinase (ALK)	Cancer
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small cell lung carcinoma (NSCLC). ALK has multiple mutants. ALK F1174S Recombinant Human Active Protein Kinase is a recombinant ALK F1174S protein that can be used to study ALK F1174S-related functions .

HY-E70642

ALK C1156Y Recombinant Human Active Protein Kinase	Anaplastic lymphoma kinase (ALK)	Cancer
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small cell lung carcinoma (NSCLC). ALK has multiple mutants. ALK C1156Y Recombinant Human Active Protein Kinase is a recombinant ALK C1156Y protein that can be used to study ALK C1156Y-related functions .

HY-E70646

ALK L1196M Recombinant Human Active Protein Kinase	Anaplastic lymphoma kinase (ALK)	Cancer
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small cell lung carcinoma (NSCLC). ALK has multiple mutants. ALK L1196M Recombinant Human Active Protein Kinase is a recombinant ALK L1196M protein that can be used to study ALK L1196M-related functions .

HY-E70645

ALK G1202R Recombinant Human Active Protein Kinase	Anaplastic lymphoma kinase (ALK)	Cancer
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small cell lung carcinoma (NSCLC). ALK has multiple mutants. ALK G1202R Recombinant Human Active Protein Kinase is a recombinant ALK G1202R protein that can be used to study ALK G1202R-related functions .

HY-112469

ERK Inhibitor II (Negative control)	ERK Insulin Receptor	Metabolic Disease
ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK). ERK Inhibitor II (Negative control) inhibits the activation of **insulin receptor**, which can be used in the study of diabetes .

HY-14243

CEP-14083	Anaplastic lymphoma kinase (ALK) Insulin Receptor VEGFR Tie	Cancer
CEP-14083 is a ATP-competitive ALK kinase inhibitor with an IC₅₀ value in enzymatic assays of 2 nM. CEP-14083 also inhibits other kinases, such as insulin receptor (IR), vascular endothelial growth factor receptor 2 (VEGFR2), angiopoietin-1 receptor (TIE2) and dual leucine zipper kinase (DLK). CEP-14083 suppresses CD274 mRNA expression and the NPM/ALK function in the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells. CEP-14083 is promising for research of lymphoma .

HY-162499

MY17	Phosphatase	Metabolic Disease
MY17 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) (IC₅₀=0.41±0.05 μM). MY17 alleviates palmitic acid (PA) -induced insulin resistance by up-regulating the expression of phosphorylated insulin receptor substrate (IRS1) and protein kinase B (AKT). By binding with PTP1B, MY17 can inhibit the activity of PTP1B, thereby improving insulin signaling and having anti-diabetic activity. MY17 can be used in the study of type 2 diabetes .

HY-125102

AZ12253801	IGF-1R	Cancer
AZ12253801 is an ATP-competitive IGF-1R tyrosine kinase inhibitor that shows ∼10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC₅₀ of 17 nmol/L. The IC₅₀ for epidermal growth factor receptor (EGFR)–driven proliferation is 440 nmol/L. Anti-tumor activity.

HY-183840

PP185	Insulin Receptor	Neurological Disease Cancer
PP185 is a **insulin receptor kinase** substrate. PP185 undergoes rapid tyrosine phosphorylation, with activity dependent on divalent cations and inhibited by insulin receptor kinase domain antibodies. PP185 can be used for the research of neuroblastoma .

HY-10262R

BMS-536924 (Standard)	Reference Standards IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
BMS-536924 (Standard) is the analytical standard of BMS-536924 (HY-10262). This product is intended for research and analytical applications. BMS-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC₅₀s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity .

HY-179572

STA-013	EGFR Akt Mitochondrial Metabolism	Metabolic Disease
STA-013 is a EphB tyrosine kinase inhibitor. STA-013 shows promising potency against EphB1 (IC₅₀ = 0.69 µM), EphB2 (IC₅₀ = 1.73 µM), and EphB4 (IC₅₀ = 1.02 µM) tyrosine kinases. STA-013 results a inhibition of the EphB phosphorylated signal, coupled with increased p-AKT/AKT signaling, to suggest insulin signaling activation. STA-013 inhibits EphB tyrosine kinase by enhancing insulin receptor beta (IRβ) signaling, and decreasing TGF-β levels in the heart. STA-013 can be used for the study of type 2 diabetes and cardiac complications (diabetic cardiomyopathy) .

HY-10524R

GSK1904529A (Standard)	Reference Standards IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
GSK1904529A (Standard) is the analytical standard of GSK1904529A (HY-10524). This product is intended for research and analytical applications. GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC₅₀s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC₅₀>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity .

HY-174645

Human IL10RA mRNA	mRNA	Metabolic Disease
Human IL10RA mRNA encodes the human interleukin 10 receptor subunit alpha (IL10RA) protein, a receptor for interleukin 10. IL10RA been shown to mediate the immunosuppressive signal of interleukin 10, and thus inhibits the synthesis of proinflammatory cytokines. It is also reported to promote survival of progenitor myeloid cells through the insulin receptor substrate-2/PI 3-kinase/AKT pathway.

HY-153503

ALK-IN-24	Anaplastic lymphoma kinase (ALK) Insulin Receptor	Cancer
ALK-IN-24 is an orally active ALK inhibitor with an IC₅₀ value of 1.7 nM. ALK-IN-24 also inhibits **insulin receptor** kinase with an IC₅₀ value of 6 nM. ALK-IN-24 suppresses the proliferation of lung adenocarcinoma cells. ALK-IN-24 inhibits ALK-driven tumor growth in xenograft mouse models. ALK-IN-24 can be used in research related to non-small cell lung cancer .

HY-111277

CEP-14513	Anaplastic lymphoma kinase (ALK) Insulin Receptor VEGFR Tie MAP3K Apoptosis	Cancer
CEP-14513 is an ALK inhibitor with an IC₅₀ of 4 nM. CEP-14513 also inhibits **insulin receptor, VEGFR2, TIE2 and DLK** kinases, but does not inhibit MET, IKKβ, or CDK1/2/5. CEP-14513 induces cancer cell apoptosis. CEP-14513 is applicable to research related to non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and diffuse large B-cell lymphoma .

HY-10252R

NVP-ADW742 (Standard) ADW742 (Standard); GSK 552602A (Standard); ADW (Standard)	Reference Standards IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
NVP-ADW742 (Standard) is the analytical standard of NVP-ADW742 (HY-10252). This product is intended for research and analytical applications. NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC₅₀ of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC₅₀ of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells .

Cat. No.	Nombre del producto

HY-L016

Protein Tyrosine Kinase Compound Library

1,578 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,578 compounds that act as a useful tool for PTKs-related drug screening and disease research.

Cat. No.	Nombre del producto	Target	Research Area

HY-P1856

Proinsulin C-peptide (human) 1 Publications Verification	Insulin Receptor PDGFR MAPKAPK2 (MK2)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Proinsulin C-peptide (human) is a peptide consisting of 31 amino acids that links the A and B chains of proinsulin to ensure its correct folding. Proinsulin C-peptide (human) inhibits the high glucose-induced increase in PDGF-β receptor protein expression and the phosphorylation of p42/p44 MAP kinase. Proinsulin C-peptide (human) increases the deformability of erythrocytes derived from type 1 diabetes, inhibits insulin-induced neointimal thickening, and suppresses the proliferation of rat aortic smooth muscle cells cultured under high-glucose conditions .

HY-119152

CMX-2043	Insulin Receptor Tyrosinase Akt	Others
CMX-2043 is a novel analogue of α-Lipoic Acid (HY-N0492). CMX-2043 is effective in antioxidant effect, activation of **insulin receptor kinase*, soluble tyrosine kinase, and Akt* phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model .

HY-P5431

Insulin receptor (1142-1153), pTyr1150	Insulin Receptor	Others
Insulin receptor (1142-1153), pTyr1150 is a biological active peptide. (Peptide used as insulin receptor tyrosine kinase substrate.)

HY-P5433

IRS1-derived peptide	Peptides	Others
IRS1-derived peptide is a biological active peptide. (This is a peptide fragment (979-989) of the insulin receptor substrate-1 containing the sequence motif YMXM known to bind to the two domains of SH2 on the 85kDa subunit of phosphoinositide 3-kinase.)

HY-P1790

Axltide	JAK	Metabolic Disease
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .

HY-P1776

[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)	Insulin Receptor	Metabolic Disease
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates .

Cat. No.	Nombre del producto	Category	Target	Chemical Structure

HY-114367

Delphinidin 3-rutinoside chloride 1 Publications Verification Delphinidin 3-O-rutinoside chloride	Structural Classification Anthocyans Flavonoids Solanum melongena L. Classification of Application Fields Phenols Polyphenols Solanaceae Plants Disease Research Fields Source Classification Cancer	Endothelin Receptor NO Synthase Myosin GLP Receptor
Delphinidin 3-rutinoside chloride is an anthocyanin component. Delphinidin 3-rutinoside chloride is isolable from the fruits of blackcurrant Ribes nigrum L. Delphinidin 3-rutinoside chloride activates the ET_B receptor and stimulates the NO/cGMP pathway. Delphinidin 3-rutinoside chloride increases cyclic guanosine monophosphate production and reduces the phosphorylation level of Myosin regulatory light chain. Delphinidin 3-rutinoside chloride stimulates GLP-1 secretion. It significantly induces relaxation of bovine ciliary muscle strips contracted by ET-1 and inhibits ET-1-induced contraction of bovine ciliary muscle strips. Delphinidin 3-rutinoside chloride is applicable to research related to type 2 diabetes .

HY-153830

LacCer (d18:1/16:0) C16 Lactosylceramide (d18:1/16:0)	Microorganisms Saccharides Monosaccharides Source Classification	Endogenous Metabolite
LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

Cat. No.	Nombre del producto	Chemical Structure

HY-153830S

LacCer (d18:1/16:0)-d3

LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0))-d₃ is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. LacCer (d18:1/16:0) is also upregulated in a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder). LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .

Cat. No.	Nombre del producto		Classification

HY-174645

Human IL10RA mRNA		mRNA Interleukin & Receptors
Human IL10RA mRNA encodes the human interleukin 10 receptor subunit alpha (IL10RA) protein, a receptor for interleukin 10. IL10RA been shown to mediate the immunosuppressive signal of interleukin 10, and thus inhibits the synthesis of proinflammatory cytokines. It is also reported to promote survival of progenitor myeloid cells through the insulin receptor substrate-2/PI 3-kinase/AKT pathway.

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

insulin receptor kinase

Inhibitors & Agonists

Bibliotecas de Screening

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products